At the news
? BEARISHIMPACT 6/10 8-K filed Aug 11, 2026 at 17:13 ET
Tango Therapeutics upsized its at-the-market (ATM) equity offering program from $100M to $400M, terminating the prior $100M facility under which $64.4M had already been sold. The new $400M shelf capacity represents a 4x increase in potential dilution, signaling aggressive capital raising for a biotech with a $4.0B market cap. This is a bearish signal as it dramatically expands the overhang of potential share issuance without any disclosed use of proceeds or operational catalyst to justify the dilution.
- Tango Therapeutics upsized its ATM offering from $100M to $400M in aggregate offering price.
- $64.4M of shares had already been sold under the prior $100M program.
- The prior $100M prospectus supplement has been terminated; the new $400M supplement includes the remaining $35.6M of unsold shares.
- The new shares are offered under the existing S-3ASR registration statement (File No. 333-291684) filed November 21, 2025.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access